Health Economics›Breast cancer›Neoadjuvant endocrine therapy, postmenopausal

Neoadjuvant endocrine therapy, postmenopausal

Breast cancer · 5 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 5 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Anastrozole and Palbociclib Variant #02	ER	R 10 015	28d	~5.7 mo	—	~5	~R 40 218 PFS proxy · indirect	1
Exemestane monotherapy Variant #01	ER	R 886	90d	~3.8 mo	~45.1 mo	~2	~R 1 771 PFS proxy · indirect	10
Letrozole monotherapy Variant #01	ER	R 371	28d	~14.5 mo	~51.3 mo	~39	~R 14 464 PFS proxy · indirect	16
Tamoxifen monotherapy Variant #01	ER	R 273	28d	~6.8 mo	~23.8 mo	~2	~R 547 PFS proxy · indirect	9
Anastrozole monotherapy Variant #01	ER	R 159	28d	~13.8 mo	~42.7 mo	~2	~R 318 PFS proxy · indirect	12

5 of 5 regimens shown